Sat Sep 21 11:18:00 UTC 2024: ## Five Below Sued for Allegedly Misrepresenting Financial Performance

**NEW YORK, Sept. 21, 2024** – Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Five Below, Inc. (NASDAQ: FIVE), alleging the company misled investors about its financial performance. The lawsuit, filed in the U.S. District Court for the Eastern District of Pennsylvania, claims Five Below downplayed the impact of macroeconomic pressures on its business, leading to a significant drop in stock price.

The lawsuit alleges that Five Below, known for its $5 and under merchandise, made false and misleading statements regarding its accelerating store traffic, merchandising opportunities, and store expansions. In reality, the company allegedly faced challenges from economic pressures that impacted its customer base and its ability to execute its business strategy.

The lawsuit points to two key events that triggered the stock price declines:

* **June 5, 2024:** Five Below admitted that lower-income customers were reducing spending due to macroeconomic pressures, leading to disappointing financial results in the first quarter of 2024. This news caused the stock price to drop by approximately 10%.
* **July 16, 2024:** Five Below announced that its CEO, Joel Anderson, had resigned, and that comparable sales for the second quarter of fiscal 2024 were down 5% year-over-year. The company also projected a significant decline in sales for the full quarter, leading to a 25% drop in stock price.

Investors who purchased Five Below securities during the relevant period are encouraged to contact Bleichmar Fonti & Auld LLP for more information. The firm is seeking to represent a class of investors who suffered losses due to the alleged misrepresentations.

**About Bleichmar Fonti & Auld LLP**

Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and shareholder litigation. The firm has been recognized for its expertise and successes, including recovering over $900 million from Tesla, Inc.’s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd.

Read More